New heart drug tested in Real-World patients
NCT ID NCT07103655
Summary
This study aims to see how well the drug mavacamten works for people with a specific form of hypertrophic cardiomyopathy (HCM), where the heart muscle is abnormally thick and causes a blockage in the middle or tip of the heart's main pumping chamber. It will involve 132 adult patients who have symptoms like shortness of breath and meet specific heart scan criteria. Researchers will measure changes in the heart's internal pressure and other markers of heart health and strain over 36 weeks of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY (HCM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.